ascendis transcon glp-1 program Pharma has granted Novo Nordisk an exclusive worldwide license for the platform to develop and commercialize products for metabolic diseases, including obesity and type 2 diabetes, along with a product-specific Technology | Ascendis Pharma
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12






























